TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17267634

Group type: EXPERIMENTAL
Intervention: Direct inoculation of standard aerobic and anaerobic blood culture bottles
Number of subjects: 4306

Group type: COMPARATOR
Intervention: Inoculation after transport in sodium polyanethol sulfonate tubes
Number of subjects: 4306
Study: 15021967

Group type: COMPARATOR
Intervention: 0.01% SDS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.1% SDS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5% SDS
Number of subjects: 12
Study: 11454075

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 100 mg/fortnight
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 400 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dietary counselling
Number of subjects: 15
Study: 9784903

Group type: EXPERIMENTAL
Intervention: Coronary rotational atherectomy (PTCRA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Plain balloon angioplasty
Number of subjects: 14
Study: 7609494

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine SR
Number of subjects: 0
Study: 3294619

Group type: EXPERIMENTAL
Intervention: Thymic Humoral Factor (THF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30654826

Group type: EXPERIMENTAL
Intervention: Neurotrauma Evidence Translation (NET) intervention
Number of subjects: 1943

Group type: COMPARATOR
Intervention: Control condition (access to clinical practice guideline)
Number of subjects: 1943
Study: 27351548

Group type: EXPERIMENTAL
Intervention: Isolated eccentric exercise (EE) group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional exercise (CG) group
Number of subjects: 36
Study: 25646326

Group type: EXPERIMENTAL
Intervention: Low α-tocopherol (<12.0 μmol/L)
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Low γ-tocopherol (<0.81 μmol/L)
Number of subjects: 1605
Study: 23696683

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 131
Study: 21849660

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 842
Study: 20439556

Group type: EXPERIMENTAL
Intervention: Dairy-rich diet (DR)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet (ER)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 120
Study: 17225981

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (surgery without treatment)
Number of subjects: 68
Study: 15129930

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (H-CHO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low carbohydrate diet (L-CHO)
Number of subjects: 12
Study: 11411657

Group type: EXPERIMENTAL
Intervention: rhuEPO therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 9674008

Group type: EXPERIMENTAL
Intervention: Limbal-based conjunctival flap
Number of subjects: 81

Group type: COMPARATOR
Intervention: Fornix-based conjunctival flap
Number of subjects: 81
Study: 7985596

Group type: EXPERIMENTAL
Intervention: OPC-18790 (mean dose 5.9 +/- 3.5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2465533

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous morphine infusion (5-48 mg, median 19 mg daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional intermittent oral or subcutaneous morphine application (10-90 mg, median 50 mg daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous morphine infusion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Long-term continuous subcutaneous morphine infusion
Number of subjects: 36
Study: 30036893

Group type: EXPERIMENTAL
Intervention: Olympus Exera III, 190 colonoscopes (190-C)
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Olympus 165 colonoscopes (165-C)
Number of subjects: 1221
Study: 28185141

Group type: EXPERIMENTAL
Intervention: Faster aspart (0.2 U/kg) administered subcutaneously in the abdomen
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Faster aspart (0.2 U/kg) administered subcutaneously in the upper arm
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Faster aspart (0.2 U/kg) administered subcutaneously in the thigh
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Faster aspart (0.02 U/kg) administered intravenously
Number of subjects: 21
Study: 26198807

Group type: EXPERIMENTAL
Intervention: Acetazolamide plus weight management
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo plus weight management
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: RGCL thickness less than the fifth percentile of controls
Number of subjects: 89
Study: 23047989

Group type: EXPERIMENTAL
Intervention: Acetaminophen (15 mg/kg [160 mg/mL])
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (volume-matched)
Number of subjects: 63
Study: 21778605

Group type: EXPERIMENTAL
Intervention: Bonding agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetone+Bonding agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silane+Bonding agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 0
Study: 19454872

Group type: EXPERIMENTAL
Intervention: Coping Strategy Questionnaire-Revised (CSQ-R)
Number of subjects: 442
Study: 16426088

Group type: EXPERIMENTAL
Intervention: Antidepressant exposure (initiation or dose increase)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Antidepressant exposure (initiation)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Neuroticism, prior attempt, and higher depressive or manic symptom ratings
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Increased antidepressant exposure
Number of subjects: 425

Group type: COMPARATOR
Intervention: Control for empirically identified confound
Number of subjects: 425
Study: 15010373

Group type: EXPERIMENTAL
Intervention: High-dose interferon-alfa (5 MIU/m(2) daily)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Low-dose interferon-alfa (3 MIU, 5 times a week)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Quality of life data
Number of subjects: 407
Study: 11768817

Group type: EXPERIMENTAL
Intervention: Protective contact isolation (isolation group) with disposable gowns and nonsterile gloves; handwashing required before entry and on leaving the room.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard precautions (control group) with handwashing and nonsterile gloves.
Number of subjects: 0
Study: 9139661

Group type: EXPERIMENTAL
Intervention: Three-drug treatment with viral protease and reverse transcriptase inhibitors
Number of subjects: 0
Study: 1662579

Group type: EXPERIMENTAL
Intervention: Vitamin C, thiopronine, and glutathione at a dose of 12 mmol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy normal subjects
Number of subjects: 0
Study: 7037156

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with methyl‐CCNU and 5‐FU
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control (no chemotherapy)
Number of subjects: 142
Study: 31496331

Group type: EXPERIMENTAL
Intervention: Pre‐consultation information on planned consultation time
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no pre‐consultation information)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Employed physicians
Number of subjects: 0
Study: 28254561

Group type: EXPERIMENTAL
Intervention: IgE immunoadsorption with IgEnio
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 27502857

Group type: EXPERIMENTAL
Intervention: Colchicine (n = 179)
Number of subjects: 360

Group type: COMPARATOR
Intervention: No-colchicine (n = 181)
Number of subjects: 360
Study: 22452364

Group type: EXPERIMENTAL
Intervention: Behavioural activation (BA) training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Behavioural activation (BA)
Number of subjects: 10
Study: 21383095

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin‐piperaquine (DP)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Artemether‐lumefantrine (AL)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin‐piperaquine (DP) without trimethoprim‐sulfamethoxazole prophylaxis (TS)
Number of subjects: 292
Study: 18614568

Group type: EXPERIMENTAL
Intervention: Comprehensive vision and eye examinations conducted by an optometrist
Number of subjects: 616

Group type: COMPARATOR
Intervention: No vision assessment or intervention
Number of subjects: 616
Study: 17097955

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg once daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 14742344

Group type: EXPERIMENTAL
Intervention: Group H (hypnotic anaesthesia) with propofol effect-site concentration maintained at 2.4 microg x ml(‐1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Group O (opioid anaesthesia) with propofol effect-site concentration maintained at 1.2 microg x ml(‐1)
Number of subjects: 46
Study: 11356779

Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg im weekly)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: COMPARATOR
Intervention: No training
Number of subjects: 54
Study: 9578508

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment at a dose of 9.5 microg/kg, administered subcutaneously every evening
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study: 7802237

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 30
Study: 3376143

Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide
Number of subjects: 15
Study: 30151225

Group type: EXPERIMENTAL
Intervention: Educational curriculum enhanced with diet and physical activity components
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard educational curriculum (control)
Number of subjects: 54
Study: 28944722

Group type: EXPERIMENTAL
Intervention: Combined strength‐training programme (full‐back squat, YoYoTM leg curl, plyometrics and sled towing exercises) performed 1 day per week (EXP1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined strength‐training programme (full‐back squat, YoYoTM leg curl, plyometrics and sled towing exercises) performed 2 days per week (EXP2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 36
Study: 26166187

Group type: EXPERIMENTAL
Intervention: Safewards model interventions
Number of subjects: 31
Study: 23948125

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily for 24 weeks
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 241
Study: 21393647

Group type: EXPERIMENTAL
Intervention: Saunders traction
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) and traction
Number of subjects: 45

Group type: COMPARATOR
Intervention: TENS only
Number of subjects: 45
Study: 19070211

Group type: EXPERIMENTAL
Intervention: 3D-conformal radiotherapy (3D-CRT) with 80 Gy in 40 fractions over 8 weeks (arm A)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 3D-conformal radiotherapy (3D-CRT) with 62 Gy in 20 fractions over 5 weeks (arm B)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 69
Study: 17023701

Group type: EXPERIMENTAL
Intervention: Sterol Bev (orange juice with 1 g plant sterols per 240 mL, twice a day for 8 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo Bev (reduced-calorie orange juice without plant sterols, twice a day for 8 weeks)
Number of subjects: 72
Study: 15124555

Group type: EXPERIMENTAL
Intervention: MammoSite per-operative brachytherapy technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard whole breast irradiation followed by a tumor bed booster dose
Number of subjects: 0
Study: 10952094

Group type: COMPARATOR
Intervention: 1 mg isoflavones/kg body weight/day (65 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2 mg isoflavones/kg body weight/day (132 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0.1 mg isoflavones/kg body weight/day (control diet)
Number of subjects: 18
Study: 8777833

Group type: EXPERIMENTAL
Intervention: High-protein meal (60 kJ per kg of body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (60 kJ per kg of body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat meal (60 kJ per kg of body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control meal (water)
Number of subjects: 0
Study: 8420693

Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin, MPH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium Valproate (Depakene, VPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10315745

Group type: EXPERIMENTAL
Intervention: Patient education intervention (nurse counseling and printed materials)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 230
Study: 29800546

Group type: EXPERIMENTAL
Intervention: Eradication therapy (oral omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for a week)
Number of subjects: 898

Group type: COMPARATOR
Intervention: No H pylori treatment (control group)
Number of subjects: 898

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 898
Study: 27881086

Group type: EXPERIMENTAL
Intervention: Machine-based unstable resistance training (M-URT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Free-weight unstable resistance training (F-URT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Machine-based stable resistance training (M-SRT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lower-extremity resistance training on even and uneven surfaces
Number of subjects: 75
Study: 24491077

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Systemic Behavior Family Therapy (SBFT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nondirective Supportive Therapy (NST)
Number of subjects: 63
Study: 24130463

Group type: EXPERIMENTAL
Intervention: Oxytocin (10 IU) injected one minute after birth
Number of subjects: 1586

Group type: COMPARATOR
Intervention: Control (no provision of prophylactic oxytocin)
Number of subjects: 1586
Study: 21443815

Group type: EXPERIMENTAL
Intervention: Higher-dose DHA (approximately 1 % dietary fatty acids)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Standard DHA (0.2-0.3 % DHA)
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Higher-dose DHA
Number of subjects: 657
Study: 18343794

Group type: EXPERIMENTAL
Intervention: PCHR-based health promotion program
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (received messages addressing cardiovascular health and sun protection)
Number of subjects: 76
Study: 17190110

Group type: EXPERIMENTAL
Intervention: High dose (200 mg/d ellagic acid)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low dose (100 mg/d ellagic acid)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (0 mg/d ellagic acid: placebo)
Number of subjects: 39
Study: 14598411

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 442
Study: 11051347

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 2 weeks
Number of subjects: 471

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 471
Study: 8719186

Group type: EXPERIMENTAL
Intervention: Surgical stimulation (skin incision) in groups 1 and 3 (each n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Norepinephrine infusion (0.1 microgram.kg‐1.min‐1) in groups 2 and 4 (each n = 10)
Number of subjects: 60
Study: 1463996

Group type: EXPERIMENTAL
Intervention: Calcium, vitamins A, C, E and selenium (in a cocktail)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 6367888

Group type: EXPERIMENTAL
Intervention: Ampicillin (2g) plus probenecid (1g)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Sulphamethoxazole‐trimethoprim (SMX‐TMP) (sulphamethoxazole 1600 mg plus trimethoprim 320 mg) four tablets twice daily for two days
Number of subjects: 201

Group type: COMPARATOR
Intervention: Sulphamethoxazole‐trimethoprim (SMX‐TMP)
Number of subjects: 201
Study: 31055791

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (1.4 ± 0.5 g/day, as mycophenolate mofetil)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tacrolimus (5 ± 3 mg/day, immediate release)
Number of subjects: 27
Study: 28950421

Group type: EXPERIMENTAL
Intervention: SB5 (adalimumab biosimilar)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Reference Adalimumab (ADA)
Number of subjects: 544
Study: 26083426

Group type: EXPERIMENTAL
Intervention: Bilateral maxillary block (group M)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scalp block (group S)
Number of subjects: 40
Study: 24639106

Group type: EXPERIMENTAL
Intervention: Epidural butorphanol (1 mg loading dose followed by 48-h infusion of 0.004 % butorphanol with 0.1 % bupivacaine at 2 mL/h)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Normal saline combined with bupivacaine (saline loading dose and 0.1 % bupivacaine infusion at 2 mL/h)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Epidural butorphanol
Number of subjects: 83

Group type: COMPARATOR
Intervention: Normal saline combined with bupivacaine
Number of subjects: 83
Study: 24021938

Group type: EXPERIMENTAL
Intervention: Guided breathing (12-min sessions daily for 8 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care alone (including non-pharmacological and pharmacological treatment)
Number of subjects: 32
Study: 20007302

Group type: EXPERIMENTAL
Intervention: Highest quartile of food folate intake (>= 253.3 microg/d) among women
Number of subjects: 109175

Group type: COMPARATOR
Intervention: Lowest quartile of food folate intake (<= 179.1 microg/d) among women
Number of subjects: 109175

Group type: EXPERIMENTAL
Intervention: Highest quartile of food folate intake (>= 229.6 microg/d) among men
Number of subjects: 109175

Group type: COMPARATOR
Intervention: Lowest quartile of food folate intake (<= 158.0 microg/d) among men
Number of subjects: 109175

Group type: EXPERIMENTAL
Intervention: Total folate intake across increasing quartiles among women
Number of subjects: 109175

Group type: EXPERIMENTAL
Intervention: Total folate intake across increasing quartiles among men
Number of subjects: 109175
Study: 18467785

Group type: EXPERIMENTAL
Intervention: Permanent acrylic resilient liner denture (RLD)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional heat‐activated acrylic resin dentures (ARD)
Number of subjects: 74
Study: 15892538

Group type: EXPERIMENTAL
Intervention: Nagel anomaloscope
Number of subjects: 79

Group type: COMPARATOR
Intervention: Holmes‐Wright Type A lantern
Number of subjects: 79

Group type: COMPARATOR
Intervention: Spectrolux lantern
Number of subjects: 79

Group type: COMPARATOR
Intervention: Beyne lantern
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ishihara plates
Number of subjects: 79
Study: 12610036

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg, infused daily intravenously for 5 days/week for 14 treatments
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo, infused daily intravenously for 5 days/week for 14 treatments
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 120
Study: 10608735

Group type: EXPERIMENTAL
Intervention: Latissimus dorsi transfers with neuronal anastomosis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Latissimus dorsi transfers without neuronal anastomosis
Number of subjects: 12
Study: 7731486

Group type: EXPERIMENTAL
Intervention: Physician supervision of the EMS system
Number of subjects: 479
Study: 2268574

Group type: EXPERIMENTAL
Intervention: Clindamycin and gentamicin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Metronidazole and gentamicin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lincomycin and gentamicin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Aural toilet alone
Number of subjects: 14
Study: 319379

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined amantadine and haloperidol
Number of subjects: 10
Study: 30763527

Group type: EXPERIMENTAL
Intervention: 2.5-mm lag screws (22 to 26 mm in length)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2.0-mm 4-hole miniplates with a gap using monocortical screws
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2.5-mm lag screws
Number of subjects: 50
Study: 28209359

Group type: EXPERIMENTAL
Intervention: 60mg Fimasartan
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: 120mg Fimasartan
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: 60mg Fimasartan + 12.5mg HCTZ
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: 120mg Fimasartan + 12.5mg HCTZ
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 272
Study: 25443384

Group type: EXPERIMENTAL
Intervention: TXA irrigation with normal saline (1 mg/mL)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal saline for irrigation
Number of subjects: 56
Study: 23911216

Group type: EXPERIMENTAL
Intervention: One extra egg per day
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Buttermilk drink containing one egg yolk
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (regular egg consumption)
Number of subjects: 97
Study: 21527854

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 18854397

Group type: EXPERIMENTAL
Intervention: rhTNF-alpha (700 ng . m(‐2) . h(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: 20% human albumin (control)
Number of subjects: 8
Study: 17089085

Group type: EXPERIMENTAL
Intervention: Omacor 1 g/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38